Flotek Industries, Inc. (FTK) Earnings Call Transcript & Summary

November 9, 2022

New York Stock Exchange US Materials Chemicals earnings 45 min

Earnings Call Speaker Segments

Bernie Colson

executive
#1

Thanks so much, and welcome, everybody — we're glad you could join us this morning. With me on the line today are John Gibson, our Chairman, Chief Executive Officer and President; Ryan Ezell, who serves as Chief Operating Officer; Seham Carson, our Interim Chief Financial Officer; James Silas, Senior Vice President of Research and Innovation; and Nick Bigney, Senior Vice President, General Counsel and Chief Compliance Officer. During this call, we'll begin with prepared comments about the business and our quarterly results. After that, we'll take whatever questions you may have. Our earnings announcement for the third quarter of 2022 has just been released and can be found on our website; we've also posted a fresh investor presentation that you're invited to download and consult while we speak. Just a reminder that this call is being webcast, and a replay will be made available on our website. Keep in mind that anything we say today about projections or what we expect to happen in the future counts as forward-looking statements. Such statements carry a variety of risks and uncertainties, a great many of which we cannot control. Those risks and uncertainties may lead actual results to differ materially from what we currently expect. Listeners should review our earnings release along with the risk factors described in our SEC filings; we also ask that you look at the reconciliations included in our earnings press release, since management might talk about non-GAAP metrics today. At this point, I'll hand things over to John.

John Gibson

executive
#2

Thanks, and good morning to all of you. We appreciate you taking part in this call about our results for the third quarter of 2022. It's something we've been eager to do — sharing today's numbers along with some context on what has happened since that quarter closed. Q3 2022 represents the second complete quarter in which Flotek has been operating under the ProFrac supply agreement, something we went through thoroughly during the prior quarter. We're glad to share that we've delivered yet another quarter of robust top-line expansion, with revenue rising 55% over the previous quarter, which comes to 4.5x higher than the same period a year ago. Like what we've heard from other major energy firms in their latest earnings releases and calls, we hold a strong conviction that we're in the opening years of a constrained supply cycle, set off by insufficient investment in infrastructure and in fresh sources of oil and gas output. Although shorter demand swings will inevitably rise and fall based on the shifting macroeconomic environment, our view is that this tight supply cycle has staying power and will lend fundamental support to crude prices across multiple years. As far as I know, unless we see major destruction of demand, there is just a single path to resolve price gains driven by supply: boosting investment throughout the whole value chain so that production can rise. That said, making the basic laws of supply and demand more complicated is the fact that operators are showing a degree of capital discipline seldom witnessed. On top of that, there is considerable strain throughout the supply chain. Even with solid oil prices, E&Ps remain focused not on expanding output but instead on keeping output steady using the smallest possible amount of capital by drilling only their best-returning wells. This emphasis on returns has produced record cash flow from oil and gas producers, with a large share of that surplus cash going back to shareholders through dividends and buybacks; in our view, the sector's focus on returns and discipline with capital aligns nicely with our approach of serving as the preferred collaborative partner for producers, since our chemistry offerings are sold to maximize the value of wells rather than merely cutting costs. Our customers among the producers tell us they get improved well results when using Flotek Chemistry, with all other factors held constant. Now I'd like to take you through the adjusted EBITDA figure that we reported for the quarter. It includes a bonus accrual of $1.9 million. Although we had not accrued for bonus payments during the first half of 2022, paying competitive compensation matters greatly if we are to keep our highly talented and driven team members, which allows us to realize the complete scope of our business model. It's been an outstanding year, and our people deserve recognition; we're glad that Q3 adjusted EBITDA as a share of revenue improved substantially once more, reaching negative 18%, compared with negative 25% in Q2 and negative 42% in Q1. Q3 was the fifth straight quarter in which our adjusted EBITDA margin improved, which shows that our business transformation is genuinely gaining traction. Ryan will give you more specifics regarding revenue and expense drivers during his remarks. To wrap up, we feel good about our capacity to keep driving more down to the bottom line as we move ahead. The investor deck we put on our site yesterday contains a slide showing how adjusted EBITDA margin has steadily gotten better across the last 5 quarters. We anticipate that pattern carrying on through the close of '22 and into 2023. Before Seham covers specifics in her remarks, I want to touch on the cash balance. Let me be clear that we think we hold the cash needed to run our business model. What we booked in Q3 in revenue was more than what we booked across all of 2021. Scaling a business this quickly calls for working capital. Because of that, we keep deploying every resource available to us so liquidity stays sufficient to fulfill the whole scope of our business. We are optimizing across every source of cash. Not long ago we brought in a third party to assist with making the order to cash collection process better, and benefits are beginning to show, which we anticipate carrying into Q4 and past that into 2023. Beyond that, we keep looking at ways to raise capital. During Q3 we could have secured an ABL, yet chose to walk away since the facility's terms weren't acceptable. We remain disciplined despite a lower cash balance, since we trust that terms obtainable once the company moves into positive adjusted EBITDA territory will be far better than what was offered to us in Q3. So weighting is the more sensible path, given how near we are to crossing that line. Finally, let me underscore that our attention is on the asset-based lending markets, not equity markets, so that our existing shareholders avoid additional dilution. Whether we succeed later depends on helping our customers' customers succeed, as opposed to the oil and gas producers that depend on our products to maximize production while minimizing cost and environmental impact. The market has shifted in a way where customers once focused only on costs are now being replaced by customers more worried about getting the most value from every well. They want the strongest initial production rates; they aim to boost total ultimate recovery, and they seek to prevent reservoir damage from careless chemistry, and every one of these sits at the front of their minds. This shift strongly plays to our core strengths and market position, and we can't wait to see how much market share we pick up in the years ahead because of it. With that, I'll hand the call to Ryan. Ryan?

Ryan Ezell

executive
#3

Thanks, John, and good morning. For Flotek, this quarter marks yet another favorable move forward, since top-line growth keeps accelerating quickly — further showing that our approach of being the go-to collaborator for sustainable, optimized chemistry and data solutions is building momentum. Let's dive straight into the operational highlights. As John noted, overall company revenue rose 55% quarter over quarter and by more than 4.5x compared with the same period in 2021; the average count of ProFrac fleets we serviced in Q3 doubled, with additional expansion carrying on into Q4 2022. Revenue from our transactional chemistry technology climbed over 10% sequentially, beating the hydraulic fracturing fleet market's growth for the fifth consecutive quarter, which further signals that we're taking market share with our tailored chemistry solutions. On the whole, Flotek handled roughly 8.4% of active U.S. frac fleets during the third quarter, an order-of-magnitude rise relative to 2021. Revenue for our data analytics segment was up 138% compared with the prior quarter, as our emphasis on core applications keeps building traction, along with momentum from successfully monitoring field gas quality using our Verax analyzers. We recently disclosed an agreement with ProFrac to provide 20 of JP3's Verax analyzers, to be used in the field so diesel fuel field gas can be displaced. So far, our Verax analyzers have been deployed on 6 ProFrac fleets, and the initial feed pack is positive. According to our industry research, making the most of field gas can cut diesel fuel consumption and lower greenhouse gas emissions by over 50%. Most importantly, the growth milestones just described were reached with 0 recordable and lost time <<inaudible>> in field operations. I'm happy with the strong performance Flotek turned in during this year's third quarter, and I thank every Flotek employee for their hard work, their contribution to these excellent results, and their commitment to collaboration, safety and service quality. Moving to a few key details for the quarter, I'd like to talk about where our mutually beneficial partnership with ProFrac stands. As a reminder, our contract with ProFrac took effect as of April 1, runs 10 years, and covers an equivalent volume of our full suite of downhole chemistries to serve 30 of their frac fleets or 70% of their total frac fleets, whichever is greater. As of Q3, we've crossed the halfway point of the original ramp, serving an average of 16 fleets, and we remain confident that we'll reach the full contract scope over the coming quarters. We also have no reason to believe our relationship is capped by the 30 fleets or 70% figures. As we keep delivering exemplary service, the structure of our arrangement gives ProFrac an incentive to maximize chemical deliveries from Flotek; in Q2, ProFrac announced the acquisition of U.S. Well Services, which closed last week. Consequently, they expect to be operating 44 active frac fleets by the end of the year. We have every confidence that we can capture that additional business, since the objective is for ProFrac to want to buy chemistry from us across its whole fleet. As we've kept saying, this deal has turned out to be transformational for Flotek and for the industry. Thanks to this deal, E&Ps now have a complete, vertically integrated completion solution that cuts emissions and provides greener chemistries, which protects air, water, land and people. Over the coming 10 years, we expect this deal to generate a backlog exceeding $2 billion in revenue for Flotek, which includes anticipated revenues above $200 million in 2023 from the ProFrac contract by itself. And that figure leaves out any effect from ProFrac's announced acquisition of U.S. Well Services. I'll keep emphasizing as well that the contract is nonexclusive, so we can bring on new customers and keep growing sales volumes with the rest of our energy chemistry customers, something we've managed to do for 5 straight quarters. Our focus is sharp on expanding this higher margin, more value-added part of our business. Turning now to the quarterly performance, we keep making steady progress in building market share and beating industry activity levels. I'm especially happy that we're seeing customer portfolio expansion with domestic as well as international E&P operators, plus service companies, as we follow through on our ongoing commitment to diversify our revenue stack and reduce the risk of customer concentration. We said before that we can double our manufacturing capacity utilization levels with no major capital investment. We're confident we can handle further significant growth without having to construct additional facilities, which will preserve cash and keep direct costs down. With the aim of lowering cost and boosting margins, we're also gaining operational efficiencies and economies of scale while revenue rises quickly each quarter. Consequently, our better leverage from higher volumes has not only helped securitize material allocation volumes in our top product lines, it has also brought about tiered volume pricing structures or raw material cost savings. On top of that, the difficult logistics environment we saw in Q2 showed improvement in Q3, with freight spend as a percentage of revenue falling as the journey toward better cost trends and more efficient operations goes on. We're actively taking direct steps to reduce freight-related inefficiencies and drive a world-class delivery network for products to our in-basin customers. Last, we made a strategic choice to discontinue the FDA-regulated hand sanitizer product line within our professional chemistries portfolio. That led to a $1 million write-down tied to associated raw materials and packaging. Even so, our professional chemistries portfolio — covering specialty chemical products meant to tackle the long-term challenges of janitorial sanitation food services in adjacent markets — will stay at the heart of our growth portfolio, since it draws on raw materials and capabilities similar to those of our EPA regulated chemistries in the energy sector. This permits greater concentration on core business activities and lowers overall regulatory costs moving forward. To sum up, I remain optimistic about what lies ahead. Our mission to deliver differentiated solutions that maximize value for our customers excites me. Put plainly, we are dedicated to protecting water quality, minimizing formation damage and enhancing the estimated ultimate recovery of every completion, all while upholding our commitment to corporate responsibility, market share growth and SG&A discipline. At this point, I will hand the call over to Seham for key financial highlights.

Seham Carson

executive
#4

Thanks, Ryan. To kick things off, I want to take everyone back through a few accounting items tied to our convertible notes and the supply agreement with ProFrac, which once again had a significant impact in the third quarter. To start, mark-to-market adjustments on the value of the convertible notes will generate noncash entries every quarter across the note's 1-year life; during Q3 2022, we moved back to a noncash loss of $4.25 million, whereas the prior quarter brought a noncash gain of $17.2 million. Let me go into a little more detail, since these figures matter and will keep introducing quarterly swings into our financial results. The $17.2 million noncash gain in Q2 2022 came mainly from a stock price on June 30, 2022 that was significantly lower than it had been on March 31, 2022. By contrast, the $4.25 million noncash loss in Q3 reflected a stock price on September 30, 2022 that was similar to June 30, 2022. However, a change in the methodology for our discount rate assumption produced a lower discount rate, a higher fair value for the note, and consequently a noncash loss for Flotek. As a reminder, these fair value adjustments will only be booked through Q2 2023 at the latest, which marks the 1-year anniversary of when the second tranche of convertible notes was issued. A 1-year mandatory conversion feature applies to all our convertible notes. Second, in the third quarter we recorded a $1.2 million noncash reduction to revenue tied to amortization of our ProFrac contract asset, versus the $737,000 revenue reduction booked in Q2. That contract asset reflects the value of the convertible notes issued as consideration for the initial ProFrac supply agreement in Q1 along with the amendment in Q2. As of the closing date of the 2 tranches, the cumulative fair value of these notes came to roughly $83 million, booked as a contract asset that will be amortized across the 10-year life of the ProFrac supply agreement and shown as a noncash reduction to revenue in our financial statements prepared under U.S. GAAP. Once more, I want to stress that these adjustments are noncash, and that additional noncash adjustments should be expected each quarter, though their size is hard to forecast since it depends on the share price and other variables. If you'd like the details on how the convertible notes get valued, our SEC filings lay out the methodology and underlying assumptions. Now, turning to the Q3 income statement. Consolidated revenue for the quarter came in at $45.6 million, which was up 55% from Q2 2022 and up 347% from the third quarter a year earlier. That revenue figure included a $1.2 million noncash reduction linked to the ProFrac contract assets. Consolidated cost of goods sold reached $47.5 million, an increase of 50% from last year. This rise mostly came from costs tied to ramping up the ProFrac supply agreement; on top of that, we recorded a $1 million inventory write-down stemming from our choice to exit our FDA-regulated hand sanitizer line. For Q3 2022, gross margin came in at negative $1.8 million, an improvement from negative $2.3 million in Q2 and a drop from positive $6.2 million in Q3 2021. That said, this gross margin figure reflected the $1.2 million noncash reduction tied to the ProFrac contract asset plus the $1 million inventory write-down. SG&A for the third quarter reached $9 million, rising 22% over Q2 2022's $7.4 million and climbing 121% versus Q3 of 2021. That figure, though, contained $1.9 million in total bonus accrual. Non-GAAP adjusted EBITDA for the second quarter was a loss of $8.4 million, falling $1.2 million from the prior quarter's loss of $7.2 million. Adjusted EBITDA also reflected the 1.9% bonus accrual I just mentioned. Turning now to the balance sheet. We closed the third quarter with $8.6 million in cash and cash equivalents, compared with $33.1 million at the close of the second quarter and $24.9 million at the close of the first quarter. That cash decline stemmed from higher inventory and accounts receivable needed to grow the top line 55% sequentially amid operating losses. As of today, we hold $11.1 million in cash. October also brought a strong finish to billing thanks to process and system improvements put in place recently, which will keep shortening how long it takes us to bill customers, cutting collection periods, and include some early payment incentives. Looking ahead to the fourth quarter of 2022 and to 2023, we aim to use our liquidity to sustain significant revenue growth while pushing toward positive adjusted EBITDA and an organically growing cash balance. Beyond that, we keep assessing possibilities for our Monahans, Texas facility and anticipate sharing an update over the next several quarters. With that, I'll hand the call back to John for his closing comments.

John Gibson

executive
#5

Thanks. Once more, I want to express appreciation to those who hold shares in our company for assisting us in opening up a remarkable possibility and protecting what lies ahead for our operations. Never before in my professional life have I worked at an organization carrying a backlog this strong. Looking ahead, I feel confident about our capacity to turn top-line expansion into profit. I also want to give credit to everyone who works here, since amid this astonishing pace of growth and the ramp-up, they have performed superbly, enabling us to carry out everything seamlessly and guaranteeing that buyers get what they require promptly, without harm, while keeping environmental concerns in mind too. My gratitude goes out to each of our team members for the excellent work accomplished. I'm grateful that you've joined this call, and I'm grateful for the backing you keep giving us. Thanks. Operator, I'll turn it back to you so we can take questions.

Don Crist

analyst
#6

I'd like to kick things off regarding the chemicals segment. Clearly, we are heading into Q4. Weather-related effects and similar things tend to occur during both the fourth and first quarters. At this moment, is there anything you're seeing that might hold back the expansion of ProFrac fleets being supplied out there — whether from a weather standpoint or some other supply chain problem?

John Gibson

executive
#7

Ryan, take it.

Ryan Ezell

executive
#8

Hello, and good morning. Right now, we must always keep in mind that Q4 could bring weather-related effects and possible shifts in activity levels. Our forecast has been built with those factors factored in. Speaking about ProFrac in particular, and considering where our fleets are expanding — mainly West Texas, South Texas, and East Texas — my sense is that our weather exposure is smaller than it would be if we were operating in the Williston area or farther up in the Northeast. Even so, we consistently account for those possibilities. I don't expect any significant interruptions, nor do I anticipate problems with our capacity to supply chemicals and/or updates and activity. What stands out is that, in my view, during this quarter, at this stage of the fourth quarter, given how seasonality usually works, there remains a fair amount of momentum as we approach the end of the year.

Don Crist

analyst
#9

So on that same trajectory you've followed over the last couple of quarters, should we still anticipate a ramp-up of roughly 7 or 8 fleets?

Ryan Ezell

executive
#10

Yes. I'd put it this way — what we're looking at is 5 to 7 on average, I would say. And as I mentioned, that figure doesn't factor in anything we might pick up from the U.S. Wells acquisition, which closed last week.

John Gibson

executive
#11

Don, we're looking at somewhere in the low to mid-20s for ProFrac, and that's also a solid question about activity. Normally, seasonality pulls activity down in Q4, but none of that is showing up at the moment. I mean, that's — with Covid, folks headed home at Thanksgiving and returned in January. As things stand, because of equipment availability, it appears they'll keep running it all the way to the New Year.

Don Crist

analyst
#12

Now moving on to JP3. Under that 20 contract, you're currently providing 6 fleets — the ProFrac fleets. How does the ramp-up look? And I realize last quarter you were somewhat reluctant to share any revenue or profitability figures related to it. But with several systems now deployed, are you ready to offer anything?

John Gibson

executive
#13

Well, the rollout is still ongoing. I believe we already had 6 deployed on ProFrac fleets; another 14 are ramping up. We keep working alongside them to complete the installs and get those units into the field. Really excited about it. What's great there is that it serves as a proof of concept. It shows how robust the thing is on a trailer. Its ruggedization is excellent, meaning it functions not merely as a sensor bolted onto a stationary site; so collaborating with ProFrac has been excellent for truly validating the technology. I remain hesitant to disclose its growth rate — although it is accelerating; and I'd say Q3 was our strongest quarter in quite some time, and I don't expect that to ease off anytime soon. I mean, we have a very solid pipeline and we're starting to gain the traction we need there. Going forward, it simply isn't a big enough revenue stream for me to have you factoring its margins in yet. I look forward to reaching the point where I need to step out and be more open about it, since those margins contribute significantly — but not at this stage, Don <<inaudible>> competitors.

Don Crist

analyst
#14

Staying on JP3 — a few months back, when we visited your offices, you mentioned potential with third parties. What's the status of those talks? And how will that marketing push get JP3 into more chemical sectors, or industries beyond the oil field generally?

John Gibson

executive
#15

On the oil field side, there's a major opening in midstream, but we're also present in power generation, where gas is being burned and gas quality matters. As a result, we're witnessing significant ramp-ups in power generation involving field gas or compressed natural gas, and folks in that sector are quite enthusiastic; so it remains tied to gas; whenever I consider it, I say it's still essentially oil within the gas business, since it links straight to natural gas and field gas. That means the power industry, the compression industry, the midstream industry, downstream — every one of those sits at the heart of JP3, and we've got solid discussions underway across all 4.

Jeff Robertson

analyst
#16

You mentioned gaining share within Flotek's chemistry for better well output. Do some kinds of reservoirs benefit far more from that chemistry, opening the door for you to grab share in particular basins?

Ryan Ezell

executive
#17

Excellent question, and honestly, in my view that's the million-dollar question when it comes to pushing forward with how we aim to grow value-add sales and lift margin as we move through 2023. Usually, in a market that's strengthening — the sort we have today, and one that can hold up — attention shifts squarely toward the greatest ultimate recovery achievable from the reservoir. And suppose you took our chemistry, especially for our prescriptive chemistry management service, which examines cuttings, produce, water, the sorts of crude formation impacts, plus the entire chemical system being applied, working with customers, above all E&P operators we deal with directly — we observe gains as large as 15% to 25% in the initial flowback and in what shows up across the overall type curves. Those are the sorts of customers, and as we put it, we want to assist the customer's customer, meaning when we partner with our service companies and the <<inaudible>> operators, selecting the right chemistry genuinely lifts overall well performance when we examine the completions we're seeing. And for us, it makes no difference. We find this in Mid-Con, we find it in the Permian Basin. We witness the identical pattern in East Texas. So I firmly believe picking the right chemistry delivers an overall better return on the investment, viewed that way.

Jeff Robertson

analyst
#18

Ryan, when you collaborate with producers on the prescriptive chemistry side of their completions, does that open a door for you to move higher-margin products?

Ryan Ezell

executive
#19

Absolutely, that's spot on. So, looking at one piece of our approach — it was about, um, being able to drive volume by partnering with service companies, delivering flawless execution, and minimizing any impact on safety and MNPT at the wellsite. And that gives us indirect contact with those asset owners, the E&P operators, which opens a pathway for us to leverage our laboratory capabilities and our differentiated chemistries to enhance the overall completion. And that's 100% of the pathway we'll be executing on as we wrap up this year and roll into 2023.

John Gibson

executive
#20

Jeff, when you look at it, our core chemistry business has expanded dramatically, and because of that, we're able to pursue value-selling loans alongside every one of those producers. That's exactly where I believe margin growth will come from as we shift from what you might call core chemistry into value-add chemistry. However, to get there, the core chemistry has to already be established, and it provides that chance to sit down in their office and walk them through how production will be boosted, how recovery will be boosted, and how the day rates on those wells will be boosted. So that opportunity is now ours, and we'll collaborate very closely with them, since this plays a role in our margin expansion story.

Jeff Robertson

analyst
#21

Jeff, when it comes to costs, are some levers more powerful than others for moving you toward positive EBITDA?

John Gibson

executive
#22

John: Yes — some moves are pretty straightforward, like bringing down what we pay for facilities, and that work is underway. With any luck, we'll be able to share something within the coming quarter or so as we consider shifting office space and similar steps, constantly seeking to cut what we spend. That said, plenty of other, more aggressive actions tied to our products and the way we deliver them are available to us. I'll hand it to Ryan now.

Ryan Ezell

executive
#23

Right. So, if we examine our total cost structure, two major factors are central to how we deliver margin improvement. The first is that our raw material situation has been favorable—both cost of goods sold and what we accomplish on the delivery side, specifically freight. When you actually dissect the figures to see where material cost of goods gains are appearing, during Q2 we began building the capability to realize economies of scale, and that reached complete implementation in Q3. At this point, we've been able to shift into tiered pricing frameworks and greater cost reductions that show up across our total material expenditure. If you went back and reviewed our days' inventory outstanding, it has gotten substantially better between Q2 and Q3, meaning we're cycling products more quickly. But the reality is that roughly a 70-day lag occurred in the map improvement. So the complete effect of material pricing won't reach us until the beginning of Q4 and what we'll observe heading into 2023, since these effects are substantial as they begin to come through, and we will see margin gains on our total material cost. The second major factor for us is that we're transporting millions of pounds of chemistry each month. So our capacity to get the most out of freight efficiency matters enormously. We finished Q2 with freight at nearly 11% of revenue. We finished Q3 down at close to 8%, and our goal is to bring that into the 6% range as we exit Q4 and enter 2023. And when you consider it, these are powerful drivers that send profitability directly through to the bottom line. This is something we're carrying out as we attain economies of scale and efficiency once the ramp begins to level off somewhat.

Jeff Robertson

analyst
#24

Jeff, regarding those transportation cost reductions tied to items you mentioned previously—namely delivering within the basin and reducing how much chemistry comes back—is that right?

Ryan Ezell

executive
#25

Ryan: Three significant factors combine to create that synergy. First, since the volume we move is so large, we could re-tender our inbound, outbound, and in-basin delivery work, and that yielded improved spot pricing along with stronger contracted rates for freight—that's the first one. Second, our efficiency has gone up. Each week we monitor what we refer to as non-value-add moves, meaning movements not tied directly to producing revenue. We also have KPIs pushing us toward week-over-week improvement until we reach that steady-state level; and the last piece involves managing returns. Being able to transfer well to well inside the basin now, rather than sending everything back to our primary operating facility in Marlow, Oklahoma, delivers meaningful savings, since that scenario involves a move—2 moves—across long distances that brought in no revenue at all. So those 3 factors represent our efforts to boost freight efficiency. And the progress beginning to show up there makes me quite pleased.

Jeff Robertson

analyst
#26

And finally, to build on what was said about JP3 — it seems like that has shifted away from being just a proof of concept regarding the effect your analyzers are having with Flotek, toward actual adoption, at least on their end. Are you noticing, or could you share, any inquiries coming in from other possible customers about deploying those analyzers? Also, is there a capacity constraint on your ability to manufacture them and get them into the field?

John Gibson

executive
#27

Yeah, those are all great questions. I'm somewhat hesitant to discuss the customers where nothing has been secured yet, though we're getting closer, since I don't want to hand a competitor any clue about where to search for deals that will close soon. Regarding the supply chain — that's a terrific question — just like every other sector, when you consider chips and electronics technology, there are supply chain challenges, but we're collaborating very closely with our suppliers. Right now, we have sufficient sensors queued up and arriving to handle all of next year, unless things go unbelievably well. And that would be wonderful. Given how many sensors we have, it would take outstanding results for us to require additional ones. Then we have a plan for 2024 that provides us with more than we need, and we're also working on the price point for that. So whenever you're in the tech industry, you must continually chase the cost curve and bring down the device's cost to remain competitive. We're doing both. We also added a leader by the name of Ron Holsey, and Ron is simply outstanding. His connections within this sector, plus his relationships with the big customers' follow-up, are generating some excellent opportunities for the pipeline; so once we land those, we'll issue press releases as we move ahead. Hopefully, Q4 will include 1 or 2 of them. And I believe early next year, we have a lot in the pipeline that are closing, where pilots are underway.

Eric Swergold

analyst
#28

Ryan, maybe you could say something about pricing. Since their own constraints have pushed your OFS customers to actively increase field prices, and they've done so by a significant amount, does that open up any space for you to charge them more?

Ryan Ezell

executive
#29

Eric, that's an excellent question, and I'd describe it as 100% of where our attention sits. John and I have gone over this thoroughly, especially when you compare oilfield services in general with the chemistry side of oilfield services. Usually, whenever the market strengthens — and that's what we're seeing right now, with capital being fairly tight when it comes to hydraulic fracturing fleet availability and hydraulic horsepower — they hold most of the leverage on the pricing side and have managed to drive spot pricing and contracted pricing up considerably compared with where things stood at the close of last year. As for chemistry, what we observe is that it's beginning to — when the service companies are our buyers, we've begun managing to pass the pricing along. And with E&Ps, price release is starting to appear and pricing is starting to rise too. But its movement doesn't line up with what we've traditionally seen from things like horsepower and iron. On those, a solid peak has already been reached. Only now are we beginning to truly see our capacity to push prices higher start to matter in Q4, and in what lies ahead for 2023. That mirrors earlier cycles I've been through during the last 20 years, in which chemistry, or chemicals, tends to move somewhat out of step. What we're observing is a possible hit to near-term margin, since we're taking on some raw material cost increases until that turn rate and that pricing can be shifted onto any of these customers — yet we've begun doing so aggressively across the board on every account.

Eric Swergold

analyst
#30

Then for my follow-up, it appears this is the first time in a while that we've seen a bonus accrual. Could you shed a bit more light on that?

John Gibson

executive
#31

Sure, happy to. When we reviewed how the year was going, in Q1 there was really no way for us to earn a bonus. Honestly, I'd say we were at a point where, without the ProFrac contract, that number would have been 0. We were growing, yes, but we still wouldn't have reached the figures we needed. So no accrual happened in Q1. Then Q2 came, we began the ProFrac contract — I'll go into more detail on that later in the call — and we assessed things. It was somewhat difficult to gauge just how fast the ramp-up would go. That put it in a gray area, and we decided against accruing in Q2. By the time Q3 arrived, we had to play catch-up for Q1, Q2, and Q3, and accounting principles say you should look at it and at minimum include Q3 and Q4 based on your expected payout, which is what we did. So I bit the bullet. One point I'd make regarding Q3 is that these steps were necessary. We needed to be normalized in 2023 without large pickups. This isn't a cash item, because until the year closes and we actually achieve the success we're after, the Board still has discretion over how much of the bonuses get paid. So it'll likely be February or March before we fully know what percentage of that $1.9 million is paid out. My hope is that we've performed well enough that a large portion is. And we're facing a market where retention is critical, and we have a team to kill for here. This team — I mean, headcount has barely increased, yet we've grown the company to where we're doing things it has never done in its history, and so — with far fewer people than it had before. So I'm very pleased with the team. It's really about retention. Everything about Q3 is, let's get the write-offs for sanitizer through. Let's get the bonus accruals done correctly. Let's make sure that what we're doing is setting up for 2023. Everything we did in Q3 is saying that we're focused on 2023 and what can happen there.

Eric Swergold

analyst
#32

My follow-up, then, concerns the related party receivable, which rose substantially during this quarter. My assumption is that this involves ProFrac, and that it merely reflects timing as the amount shifts from cash into a related party receivable?

Seham Carson

executive
#33

Correct. So the AR increase is what you're referring to. Given that activity has grown and the ramp-up has occurred, we've genuinely examined our processes in an effort to accelerate this. And I believe some advantages from the improvements we've implemented in systems and manual processes will become apparent at the close of this year.

Eric Swergold

analyst
#34

Then for my last question, is there anything new you can share regarding customers in the U.S., customers in the Middle East, or perhaps with deepwater beginning to recover — anything on deepwater?

Ryan Ezell

executive
#35

Sure. What I'd say is that, on the whole, our business in the Middle East keeps expanding. That said, if you set it against the overall revenue gains coming from our U.S. hydraulic fracturing operation, it isn't on that same scale, though we are seeing a great deal of value-add sales happening there involving our complex nano-fluids stimulation services, and so on; we're deliberate about which customers we take on in that region, purely because of the specific return on cash and how quickly payment terms convert to DSO there, since it's somewhat tougher in certain of those areas, yet growth in the Middle East is real. We're extremely enthusiastic about our efforts there and about the market share gains we're driving, which sit in the double-digit range for the stimulation business across North America land. Beyond that, we're seeing additional national growth in Latin America with regard to the chemistry business; as for deepwater, activity is still flowing through our Raceland, Louisiana plant, which handles a great deal of trans mix and loading for deepwater operations tied to cementing profit movements, and similar work. Even so, I wouldn't claim what we've observed there has been big enough to make a material difference when set beside our growth in the North American stimulation business.

John Gibson

executive
#36

Alright, thank you so much. I’m grateful that everyone has remained on the call. At the end here, I’d like to address 2 items, and after that we’ll follow up with you on the calls afterward, for those who dial in. First, there are 2 items to consider. One is cash, and the other is margin. Those are the 2 most important items we focus on here; regarding cash, you can feel assured that skipping an ABL in Q3 and waiting for a favorable moment to obtain cash with reduced rates and fewer restrictions would signal how confident we are about our cash position. Although it may be low, we do not anticipate any problem with working capital as we move through Q4. That’s why we could decline it and seek better terms. It also tells you for sure that our margins are getting better, and we do have a projection of reaching the point where we are at positive adjusted EBITDA. That’s very exciting. I’m not saying precisely when, and we won’t provide guidance on that, but we definitely have that projected, or we would not have turned down the cash with the confidence that we did; so be confident that our cash position is okay, we are, and be confident in our capacity to manage the growth in our margins that is required to be a profitable company. I’d remind you, we are only 5 months into the contract with ProFrac, that’s all. And the hardest thing in my career is to grow revenue. And once you have the revenue, it becomes a blocking and tackling exercise to bring your costs into line so that you’re a profitable company. We are now in the blocking and tackling part of this, where we have a lot of work to do. But Ryan and the team, Seham, Nick, James, Bernie, they’re all on top of that; and we’re confident that we are the right company to take a look at in 2023, and we’re excited about what the future holds; and we appreciate you guys, and we look forward to talking to you again soon.

Operator

operator
#37

That brings us to the end of this call. We appreciate your joining us for today's presentation. You're welcome to disconnect at this time.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Flotek Industries, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Flotek Industries, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Flotek Industries, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.